New Tracers for Prostate Cancer Imaging

Slides:



Advertisements
Similar presentations
NPCA data collection on men undergoing radical surgery for prostate cancer Paul Cathcart, NPCA Urology Project Coordinator.
Advertisements

PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
Imaging modalities in prostate cancer
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
Is there a role for adjuvant/neoadjuvant chemotherapy in High risk prostate cancer? Giuseppe Procopio Fondazione IRCCS Istituto Nazionale Tumori Milano.
Steven Joniau Filip Ameye
PROGRESS IN MANAGEMENT OF PROSTATE CANCER Presented by Dr. J. Nkusi on the October 2007, 38 th Congress of the Botswana Medical Association.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
Prostate cancer: To screen or not to screen – To treat or not to treat Dr Oliver Klein – Medical Oncologist.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99 mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT,
Howard M. Sandler, MD University of Michigan Medical School
A 74 year old man underwent open prostatectomy due to moderate to severe urinary symptoms unresponsive to medical therapy. Preoperative PSA was 4.1 Postoperatively.
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
Prostate Support Group Dr Duncan McLaren Consultant Oncologist.
CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
PATTERNS OF CARE OF PATIENTS WITH AN OCCULT LOCOREGIONAL RELAPSE ON CHOLINE PET/CT AFTER A PRIOR CURATIVE TREATMENT FOR LOCALIZED PROSTATE CANCER Choline.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Detected by 11 C-Choline PET/CT RJ Karnes MD, FACS Vice-Chair Associate Professor and.
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital.
Choline PET/CT Robert S. Bridwell MD MBA Founder and CMO Appian 360
Nuclear imaging for prostate cancer: What’s new?
Volume 64, Issue 5, Pages (November 2013)
Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer 
Using PET/CT in Prostate Cancer
This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in.
Carcinoma of Prostate Issam S. Al-Azzawi, MD,FICMS,FEBU By
Using PET/CT in Prostate Cancer
Klinikum rechts der Isar, Technische Universität München
Prostate cancer: Radioisotope diagnostic/ therapeutic methods
European Journal of Cancer
Surgical Treatment in Locally Advanced Prostate Cancer
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital
Bladder Cancer and Prostatic Cancer
Fig. 4. Follow-up abdominal computed tomography scans after six cycles of S-1/cisplatin combination chemotherapy (A, B) and 68 months after surgery (C,
Post Op Positive Apex Margins Case 3: Prostate_3
Nat. Rev. Urol. doi: /nrurol
WFNMB Post Congress Symposium Prostate Cancer: PET and Theranostics Cairns Convention Centre, Queensland, Australia April 26-27, 2018 THURSDAY 26th APRIL.
Fig. 10. MIP (A, C) and axial non contrast fused 18F-FDG PET/CT (B) in 20-year-old man with ALK positive anaplastic large cell lymphoma. A. Patient had.
Michael Kamerick Sequoia Consulting Twitter: #AMIA2017
Post Op Positive Seminal Vesicle Case 4: Prostate_4
Prostate Cancer: Highlights from 2006
Jaden D. Evans, MD, Krishan R
Volume 73, Issue 5, Pages (May 2018)
Volume 54, Issue 4, Pages (October 2008)
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
Apollo Gleneagles Hospitals,
Volume 64, Issue 5, Pages (November 2013)
What is New in Hormone Therapy for Prostate Cancer in 2007?
Updates in Detection and Management of BCRPC
Volume 62, Issue 1, Pages (July 2012)
Nat. Rev. Urol. doi: /nrurol
11C-Choline Positron Emission Tomography for the Evaluation after Treatment of Localized Prostate Cancer  I.J de Jong, J Pruim, P.H Elsinga, W Vaalburg,
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies  Steven P. Rowe, Kenneth J.
European Urology Oncology
Figure 1. Non-biochemical recurrence rate for the entire population (n = 122). From: Salvage radiation therapy for prostate cancer patients after prostatectomy.
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Nat. Rev. Urol. doi: /nrurol
Long-Term Hormonal Therapy: Who Would Benefit?
Prostate Cancer Update
European Urology Oncology
Constantinos Zamboglou, Matthias Eiber, Thomas R
Volume 4, Issue 1, Pages (February 2006)
History: 71 yo male post radical prostatectomy 4 years ago for Gleason 4+5 prostate cancer Pre-op staging CT and MDP bone scan were negative for metastatic.
Presentation transcript:

New Tracers for Prostate Cancer Imaging Stefano Fanti

Imaging of Prostate Cancer

OLD TRACERS NEW TRACERS CURRENT TRACERS NEW TRACERS Many years ago, we published this work in JNM about the accuracy of PET/CT for the intra prostatic detection of cancer foci. We studied 31 patients and compared PET results with histopathology on a sextant basis.

Is Choline PET outdated ?

RECURRENCE Patient treated with radical prostatectomy for PCa 4+4, T3bN1(2/24) MxR0, presentation PSA=12.1 ng/mL in April 2009. Biochemical relapse occurred 11 months after surgery, with rising PSA levels (PSA 2.1 ng/mL in 10/2010). Patient was addressed to ADT with continuous scheme (bicalutamide + LH-RH inhibitor), experiencing PSA response (PSA values <0.2 ng/mL). In October 2012 biochemical relapse occurred with rising PSA levels during ADT . Patient was subsequently referred to 11C- choline PET/CT with PSA value of 0.88 ng/mL, that showed a diffuse bone metastatic invasion together with lymph-node relapse. The patient was addressed to chemotherapy (Docetaxel) according to the diffuse metastatic spread revealed by 11C-choline PET/CT.

Many years ago, we published this work in JNM about the accuracy of PET/CT for the intra prostatic detection of cancer foci. We studied 31 patients and compared PET results with histopathology on a sextant basis.

RECURRENCE Prostatectomy PSA 1.3 ng/Ml DT 3 months BS neg

RECURRENCE Prostatectomy PSA 0.9 ng/mL BS neg

11C-CHOLINE

CHOLINE PET/CT Many years ago, we published this work in JNM about the accuracy of PET/CT for the intra prostatic detection of cancer foci. We studied 31 patients and compared PET results with histopathology on a sextant basis.

CURRENT TRACERS Many years ago, we published this work in JNM about the accuracy of PET/CT for the intra prostatic detection of cancer foci. We studied 31 patients and compared PET results with histopathology on a sextant basis.

PSMA TRACERS

68Ga-PSMA 18F-CHOLINE

Images courtesy of prof Haberkorn - Heidelberg 68Ga-PSMA 18F-CHOLINE Images courtesy of prof Haberkorn - Heidelberg

392 ARTICLES SINCE 2012 128 ARTICLES IN 2017 24 ARTICLES IN MAY

68Ga-PSMA

Only 1 exam

PSMA PET/CT Many years ago, we published this work in JNM about the accuracy of PET/CT for the intra prostatic detection of cancer foci. We studied 31 patients and compared PET results with histopathology on a sextant basis.

Impact

Impact

NEW TRACERS

Fluciclovine

Many years ago, we published this work in JNM about the accuracy of PET/CT for the intra prostatic detection of cancer foci. We studied 31 patients and compared PET results with histopathology on a sextant basis.

Many years ago, we published this work in JNM about the accuracy of PET/CT for the intra prostatic detection of cancer foci. We studied 31 patients and compared PET results with histopathology on a sextant basis.

Detection Rate BCR with > 1.0 PSA < 2.0

Detection Rate BCR with PSA < 1.0

Gleason 5+4 (01/30/2007) presenting with a T2b nodule and PSA of 5.4 High grade prostate cancer involving 6/12 cores 21 months of androgen blockade Intensity modulated pelvic XRT in 2007 PSA nadir in February 2011 was 0.11 Biochemical recurrence in 2011 MIP PET 68Ga RM2 MIP PET 68Ga PSMA 68GA-BOM Images courtesy of prof Iagaru - Stanford

NEW TRACERS PET/CT Many years ago, we published this work in JNM about the accuracy of PET/CT for the intra prostatic detection of cancer foci. We studied 31 patients and compared PET results with histopathology on a sextant basis.

68GA-BOM 18F-FACBC 68GA-PSMA 11C-CHOLINE 18F-PSMA

Many years ago, we published this work in JNM about the accuracy of PET/CT for the intra prostatic detection of cancer foci. We studied 31 patients and compared PET results with histopathology on a sextant basis. THANK YOU